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Abstract: The platinum-based chemotherapy regimen FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxali-
platin) is currently used as a standard treatment for patients with unresectable pancreatic cancer. FOLFIRINOX is 
associated with severe toxicities, including neutropenia, febrile neutropenia, and anorexia; however, there are cur-
rently no reliable biomarkers to predict its efficacy and safety. Several studies of patients with various cancers have 
shown that tumor expression of excision repair cross-complementing (ERCC) proteins and glutathione S-transferase 
Pi (GSTPi) correlates with the response to platinum-based chemotherapies. Therefore, in this study, we examined 
the associations between expression of ERCC proteins and GSTPi and the safety and efficacy of FOLFIRINOX in 34 
patients with unresectable pancreatic cancer. ERCC1, ERCC2, ERCC4, and GSTPi expression were examined by im-
munohistochemical staining of tumor specimens and the results were correlated with overall survival, progression-
free survival, response rate, disease control rate, and the frequency of grade 3-4 neutropenia and non-hematologic 
toxicities. We found that ERCC1, ERCC2, ERCC4, and GSTPi were expressed in tumor samples from 64%, 24%, 18%, 
and 64% of patients, respectively. Notably, there were no statistically significant associations between the expres-
sion pattern of any of the proteins and either the clinical outcomes or the frequency of grade 3-4 neutropenia or 
grade 3-4 anorexia. Collectively, these data indicate that tumor expression of ERCC1, ERCC2, ERCC4, and GSTPi 
does not predict the safety or efficacy of FOLFIRINOX in patients with pancreatic cancer.
Keywords: Pancreatic cancer, FOLFIRINOX, predictive factor, ERCC1, ERCC2, ERCC4, GSTPi, immunohistochemis-
try, biomarker
Introduction
The effectiveness of the platinum-based regi-
men FOLFIRINOX (oxaliplatin, irinotecan, flu- 
orouracil, and leucovorin) as first-line chemo-
therapy in patients with metastatic pancreatic 
cancer was first reported in 2011 [1]. In Japan, 
FOLFIRINOX obtained regulatory approval for 
the treatment of pancreatic cancer in Decem- 
ber 2013. FOLFIRINOX and nab-paclitaxel plus 
gemcitabine are both currently employed as 
standard chemotherapy regimens for unresect-
able pancreatic cancer in patients with good 
Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS) [2].
FOLFIRINOX is associated with severe toxici-
ties, including neutropenia, febrile neutropenia, 
thrombocytopenia, anorexia, fatigue, and diar-
rhea, which frequently require dose reduction 
or treatment interruption. A phase 2 study of 
FOLFIRINOX in Japanese patients with pancre-
atic cancer reported high frequencies of toxici-
ties, including grade 3 or 4 neutropenia (77.8% 
of patients), febrile neutropenia (22.2%), and 
anorexia (11.1%) [3]. These side effects could 
lead limited use of FOLFIRINOX. Recently, a 
modified FOLFIRINOX regimen showed satis- 
factory efficacy with less toxicity in pancreatic 
cancer patients [4-6]. However, there have be- 
en no direct comparisons of the safety and ef- 
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ficacy of FOLFIRINOX, modified FOLFIRINOX, 
and nab-paclitaxel plus gemcitabine, making it 
difficult to select the optimal treatment regi-
men for pancreatic cancer patients. There is 
thus great interest in discovering biomarkers 
that can predict the efficacy and safety of 
FOLFIRINOX in this disease.
DNA repair is an important role in resistance 
to platinum agents that act inhibiting DNA 
replication and transcription by binding to a 
DNA molecule in the form of platinum-DNA-
adducts [7]. Excision repair cross-complement-
ing (ERCC) protein 1, ERCC2, and ERCC4 are 
key proteins involved in the nucleotide exci- 
sion repair pathway, which is a major compo-
nent of the DNA repair response [8, 9]. Previous 
work identified a correlation between expres-
sion of ERCC1 protein or mRNA, as measured 
by immunohistochemistry (IHC) or reverse-tran-
scription polymerase chain reaction (RT-PCR) 
respectively, and the response to platinum 
agents, including oxaliplatin, in patients with 
gastrointestinal cancer, ovarian cancer, and 
non-small cell lung cancer (NSCLC) [10-19]. A 
single nucleotide polymorphism in ERCC2 (Lys- 
751Gln) is associated with the survival of pa- 
tients with colon cancer treated by oxaliplatin-
based regimens [20], supporting the possible 
utility of ERCC proteins as biomarkers of the 
response to platinum chemotherapies. Another 
potential biomarker is glutathione S-transfer- 
ase Pi (GSTPi, also known as GSTP1). GSTs are 
a family of detoxification enzymes found in all 
aerobic organisms and play protective roles in 
preventing cellular damage from toxic com-
pounds, including chemotherapeutic agents 
[21]. Polymorphisms have been detected in 
many of the genes encoding the main GST iso-
enzymes, including GSTPi. One polymorphism 
in GSTPi is reportedly related to the sensitivity 
of colorectal cancer to platinum-based com-
pounds [22].
There have been few reports examining the 
correlation between ERCC1, ERCC2, ERCC4, 
and GSTPi expression and the response to plat-
inum-based chemotherapies in patients with 
pancreatic cancer [16, 18, 23]. To address this 
knowledge gap, we examined the expression of 
these four candidate biomarkers in pancrea- 
tic cancer specimens from patients treated 
with FOLFIRINOX and investigated their rela-
tionship to various clinicopathological factors, 
including patient outcomes.
Material and methods
Patients and study design
This was a single-center, retrospective cohort 
study of 34 patients with unresectable pancre-
atic cancer who started treatment with FOLFI- 
RINOX between December 2013 and Septem- 
ber 2015. All patients were selected for this 
study based on histologically confirmed pan- 
creatic adenocarcinoma and the availability of 
adequate tissue derived from (i) endoscopic 
ultrasonography-guided fine-needle aspiration 
(EUS-FNA) of the primary pancreatic tumor or 
lymph node metastasis, (ii) fine-needle biopsy 
from liver metastasis, (iii) forceps biopsy of 
bile duct-invasive tumor or duodenum-invasive 
tumor, or (iv) previously resected surgical speci-
mens from primary tumors. Clinical data were 
obtained by retrospective chart review. All pa- 
tients had an ECOG PS score of 0 or 1 [2] and 
had adequate bone marrow and renal funct- 
ion. Evaluation of the response to chemothera-
py (complete response [CR], partial response 
[PR], stable disease [SD], and progressive dis-
ease [PD]) was based on the Response Eva- 
luation Criteria In Solid Tumors guidelines [24]. 
All patients provided informed consent. This 
Table 1. Clinical characteristics of the pa-
tients (n = 34)
N (%)
Age, median (range) 61 (42-73)
Gender
    Male 20 (59)
    Female 14 (41)
Line
    1st line therapy 26 (76)
    2nd line therapy 3 (9)
    3rd line therapy 5 (15)
UICC Stage
    III 3 (9)
    IV 31 (91)
Performance status (ECOG) 
    0 16 (47)
    1 18 (53)
Initial dose modification 17 (50)
Neutrophil-to-lymphocyte ratio ≥5 8 (24)
Abbreviations: ECOG, Eastern Cooperative Oncology 
Group; UICC, Union for International Cancer Control.
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study was approved by the Institutional Review 
Board of Kanagawa Cancer Center.
Immunohistochemistry
IHC was performed using standard procedures. 
In brief, formalin-fixed, paraffin-embedded tis-
sue samples were cut into 4-μm-thick sect- 
ions, deparaffinized and rehydrated. Endogen- 
ous peroxidase was blocked by incubation with 
3% hydrogen peroxide for 10 min at room tem-
perature, and antigen retrieval was achieved by 
incubating sections for 15 min at 121°C in 
citrate buffer (pH 6.0). Sections were then in- 
cubated with one of the following primary anti-
bodies for 60 min at room temperature: anti-
ERCC1 (#12345, Cell Signaling Technology, 
Danvers, MA, USA, 1:100 dilution), anti-ERCC2 
(10818-1-AP, Proteintech, Rosemont, IL, USA, 
1:75), anti-ERCC4 (IHC-00263, Bethyl Labora- 
tories, Montgomery, TX, USA, 1:300), and anti-
GSTP1 (#3369, Cell Signaling Technology, 1: 
800). After washing, sections were incubated 
for 30 min at room temperature with second- 
ary antibody and polymer detection system (N- 
Histofine, Nichirei Biosciences, Tokyo, Japan) 
and then stained with chromogen (DAB Chro- 
mogen Kit, Nichirei Biosciences). Finally, the 
sections were counterstained with hematoxy- 
nuclear staining. GSTPi expression was con- 
sidered to be positive when the intensity and 
percentage scores were 2 or 3 and the tumor 
cells showed nuclear or cytoplasmic staining. 
All other staining patterns were considered 
negative. This evaluation system was reported 
in the past study [10].
Clinical endpoints and statistical analysis
The clinical outcomes investigated were overall 
survival (OS), progression-free survival (PFS), 
response rate (RR), disease control rate (DCR), 
and the frequency of grade 3-4 neutropenia 
and non-hematologic toxicities. Associations 
between protein expression and OS or PFS 
were analyzed using the Kaplan-Meier meth- 
od and evaluated using the log-rank test. Re- 
lationships between protein expression and 
RR, DCR, grade 3-4 neutropenia frequency, 
and grade 3-4 anorexia frequency were evalu-
ated by Fisher’s exact test. Multivariate Cox 
regression analysis was used to evaluate rela-
tionships between clinical outcomes and pro-
tein expression or clinicopathological varia- 
bles, such as ECOG PS [2] and neutrophil-to-
lymphocyte ratio [25], which are known predic-
tive factors in several malignancies.
Figure 1. Immunohistochemical staining of patient specimens. A-D. Repre-
sentative images of immunohistochemical staining of the four proteins to 
illustrate typical intensity and percentage staining scores (both on a scale of 
1-3). A. Excision repair cross-complementing (ERCC): intensity score 1, per-
centage score 3. B. ERCC2: intensity score 3, percentage score 2. C. ERCC4: 
intensity score 3, percentage score 2. D. Glutathione S-transferase Pi, inten-
sity score 3, percentage score 3. Scale bar = 500 μm.
lin and dehydrated for mount- 
ing.
Evaluation of immunohisto-
chemical staining
Protein staining was assess- 
ed independently by two in- 
vestigators who were blinded 
to the patients’ identities and 
clinical outcomes. If the in- 
vestigators’ opinions differed, 
the final result was decided 
by consensus. Slides were 
analyzed by light microscopy. 
Staining was scored for inten-
sity (1, weak; 2, moderate; 3, 
strong) and the percentage of 
cells positively stained (1, 1% 
to 9.9%; 2, 10% to <49.9%; 3, 
50% to 100%). ERCC1, ERC- 
C2, and ERCC4 expression 
was considered to be positive 
when the intensity and per-
centage scores were 2 or 3 
and the tumor cells showed 
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Continuous variables were expressed as the 
mean and 95% confidence interval (CI) for mul-
tivariate Cox regression analysis or the median 
and range. Categorical variables were express- 
ed as counts and percentages, and differences 
in categorical variables were analyzed using 
Fisher’s exact test. A P value <0.05 was regard-
ed as statistically significant. Statistical analy-
ses were performed using JMP Pro version 
12.2.0 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
We enrolled 56 patients with unresectable 
pancreatic cancer who started treatment with 
FOLFIRINOX at our institution between Dece- 
mber 2013 and September 2015. Thirty-four 
of the 56 patients had adequate tissue speci-
mens available for IHC and were included in the 
study. The median age of the 34 patients was 
61 years (range, 42-73 years). The patient char-
acteristics are presented in Table 1. 
Expression of biologic markers and relation-
ships to clinical outcomes
Of the 34 specimens collected, 13 were from 
primary pancreatic tumors, 11 were from liver 
metastases, 3 were from duodenum-invasive 
tumors, 2 were from bile duct-invasive tumors, 
and 1 was from a lymph node metastasis. The 
four remaining samples were obtained from 
previously resected surgical specimens.
IHC analysis revealed that ERCC1 was express- 
ed in 22 of the 34 specimens (64%) examined 
and ERCC2, ERCC4, and GSTPi were expressed 
in 24%, 18%, and 64% of specimens, respec-
tively (Figure 1). ERCC1 and ERCC4, which form 
an enzyme complex in the nucleotide excision 
repair pathway, were co-expressed in 6 sam-
ples (18%). ERCC1, ERCC2, ERCC4, and GSTPi 
were all co-expressed in only 2 of the 34 sam-
ples (6%). None of the proteins were detected 
by IHC in normal (non-tumor) cells.
The patient clinical outcomes are summarized 
in Table 2. There were no significant differenc-
es between outcomes in patients with posi- 
tive or negative expression of ERCC1, ERCC2, 
ERCC4, or GSTPi. Kaplan-Meier OS and PFS 
curves stratified according to protein expres-
sion are shown in Figure 2. Although the differ-
ences in OS and PFS between patients with 
positive vs. negative protein expression were 
not statistically significant, the median PFS 
tended to be longer for patients expressing 
ERCC1 (154.5 days vs. 92 days, P = 0.266; 
Figure 2A) and ERCC2 (252 days vs. 92 days, 
P = 0.222; Figure 2B). Similarly, we observed 
no significant differences in RR or DCR betw- 
een patients with positive or negative expres-
sion of any of the proteins, but RR tended to 
be better for patients expressing ERCC1 (23% 
vs. 0%, P = 0.095; Table 2). Finally, we did not 
detect any significant correlations between the 
protein expression pattern and the frequency 
of either grade 3-4 neutropenia or grade 3-4 
anorexia (Table 3).
Table 2. Relationship between expression of biological markers and clinical outcomes
N (%) OS [95% CI] (days) PFS [95% CI] (days) RR (%) DCR (%)
ERCC1 Positive 22 (64) 391 [177, 616] 154.5 [57, 270] 23 64
Negative 12 (36) 203.5 [123, 561] 92 [30, 160] 0 67
P-value 0.503 0.266 0.095 0.583
ERCC2 Positive 8 (24) 399.5 [123, 821] 252 [47, 342] 13 75
Negative 26 (76) 217.5 [162, 561] 92 [57, 160] 15 62
P-value 0.623 0.222 0.666 0.402
ERCC4 Positive 6 (18) 216 [124, 821] 178.5 [35, 309] 17 67
Negative 28 (82) 391 [177, 497] 127 [57, 182] 14 64
P-value 0.750 0.911 0.647 0.649
GSTPi Positive 22 (64) 240 [162, 489] 97 [48, 270] 9 64
Negative 12 (36) 391 [124, 616] 129 [36, 182] 25 67
P-value 0.882 0.362 0.225 0.583
Abbreviations: CI, confidence interval; DCR, disease control rate; ERCC, excision repair cross-complementing; GSTPi, glutathi-
one S-transferase Pi; OS, overall survival; PFS, progression-free survival; RR, response rate.
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To further assess the possible associations of 
clinicopathological factors on OS and PFS, we 
performed multivariate Cox regression analysis 
(Tables 4 and 5, respectively). These analyses 
Figure 2. Kaplan-Meier curves for patient survival. (A-D) Overall survival (OS) and progression-free survival (PFS) of 
patients stratified by tumor expression of excision repair cross-complementing (ERCC) 1 (A), ERCC2 (B), ERCC4 (C), 
and glutathione S-transferase Pi (GSTPi) (D). 
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revealed that an ECOG PS of 1 was significantly 
associated with OS (hazard ratio [HR]: 9.50, 
95% CI: 2.25-40.07, P = 0.002) and PFS (HR: 
4.95, 95% CI: 1.75-14.00, P = 0.003). Similarly, 
a neutrophil-to-lymphocyte ratio ≥5 was sig- 
nificantly related to both OS (HR: 9.50, 95% CI: 
2.25-40.07, P = 0.002 and HR: 6.02, 95% CI: 
1.20-30.29, P = 0.03).
Discussion
To our knowledge, this is the first study to 
examine the relationship between tumor ex- 
pression of ERCC1, ERCC2, ERCC4, and GSTPi, 
as assessed by IHC, and the response to 
FOLFIRINOX in pancreatic cancer patients. We 
found that none of these proteins could serve 
as predictive biomarkers in our patient cohort. 
Although the results did not reach the level of 
statistical significance, however, we did observe 
a trend between positive tumor expression of 
ERCC1 and PFS and RR, and between expres-
sion of ERCC2 and PFS.
The use of FOLFIRINOX for pancreatic cancer 
has been limited by its severe toxicities com-
bined with better patient responses to gem-
citabine [1, 3]. However, there have been no 
randomized controlled trials to directly com-
pare the efficacy of FOLFIRINOX and nab-pacli-
taxel plus gemcitabine, both of which are stan-
dard chemotherapy regimens for unresectable 
pancreatic cancer patients with good ECOG PS. 
Moreover, there are no established predictive 
biomarkers for the response to FOLFIRINOX, 
with the exception of gender and serum CA19-
9, which are positive predictors of the response 
[26]. There is thus an unmet need to identify 
reliable biomarkers that can predict patient 
response to FOLFIRINOX.
Several reports have identified a relationship 
between tumor ERCC1 expression detected by 
IHC and the response to platinum agents, in- 
cluding oxaliplatin, in patients with gastrointes-
tinal cancer, ovarian cancer, and NSCLC [10, 
12, 18, 19]. In addition, ERCC1 mRNA expres-
sion levels have been reported to correlate with 
resistance to platinum agents in patients with 
esophageal, gastric, colon, and ovarian can-
cers and NSCLC [11, 13-15, 17, 19]. Only one 
study in pancreatic cancer has demonstrated a 
significant relationship between ERCC1 expres-
sion and the response to FOLFIRINOX, and that 
involved measurement of ERCC1 mRNA, not 
protein, levels [16]. 
The results of the present study contrast with 
earlier data showing a correlation between high 
ERCC1 expression and resistance to platinum 
agents in gastrointestinal cancer, ovarian can-
cer, and NSCLC [10-19]. However, our findings 
are consistent with other studies reporting no 
relationship between ERCC1 expression and 
response to platinum agents in pancreatic 
cancer, colon cancer, and neuroendocrine tu- 
mors [27-30]. We speculate that these differ-
ences may be explained partly by the different 
types of cancer studied and partly by differ- 
ences in methodology. The two previous stud-
ies using IHC to detect ERCC1 expression in 
pancreatic cancer concluded that ERCC1 levels 
did not correlate with the response to plati- 
num agents [18, 23]. In contrast, the single 
study examining ERCC1 mRNA expression in 
pancreatic cancer did find an association with 
the response to platinum agents [16]. Consis- 
tent with the earlier studies, we found no evi-
dence of a significant relationship between 
ERCC1 protein expression, as detected by IHC, 
and the response of pancreatic cancer patients 
to FOLFIRINOX. 
Our failure to detect a relationship between 
protein expression and FOLFIRINOX response 
could be due to the small number of tumor 
cells evaluated in the sections. Only four surgi-
cally resected specimens were available in this 
Table 3. Associations between the expression 
of biological markers and the frequency of 
grade 3-4 neutropenia and anorexia
Grade 3-4  
neutropenia (%)
Grade 3-4 
anorexia (%)
ERCC1 Positive 91 14
Negative 75 8
P-value 0.225 0.556
ERCC2 Positive 88 13
Negative 85 12
P-value 0.666 0.678
ERCC4 Positive 100 0
Negative 82 14
P-value 0.353 0.441
GSTPi Positive 86 14
Negative 83 8
P-value 0.590 0.556
Abbreviations: ERCC, excision repair cross-complement-
ing; GSTPi, glutathione S-transferase Pi.
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study, and the remaining 30 
specimens were collected by 
EUS-FNA or biopsy of liver 
metastases, bile duct-invas- 
ive tumors, or duodenum-in- 
vasive tumors. Biopsied spe- 
cimens, especially those ob- 
tained by EUS-FNA, are gene- 
rally small, and pancreatic 
cancers have abundant fibro- 
tic stroma [31]. A study of sur-
gically resected pancreatic 
cancer specimens reported 
a significant correlation be- 
tween high ERCC1 expres-
sion, as detected by IHC, and 
shorter OS and recurrence-
free survival [32]. 
This study has some limita-
tions. First, as mentioned ab- 
ove, the sample size was re- 
latively small and may have 
been insufficient to detect 
positive associations. Sec- 
ond, we used only IHC to 
detect ERCC1, ERCC2, ER- 
CC4, and GSTPi expression, 
and use of a complementary 
method, such as mRNA an- 
alysis by RT-PCR, may provi- 
de more robust data. Third, 
the proportion of tumors po- 
sitive for ERCC2 (24%) and 
ERCC4 (18%) was low, which 
may have complicated the 
interpretation of results. Fi- 
nally, the specificities of the 
antibodies used for IHC are 
unclear, potentially resulting 
in incorrect expression data 
[33, 34].
Conclusions
In conclusion, this is the first 
report to demonstrate that 
tumor expression of ERCC1, 
ERCC2, ERCC4, and GSTPi in 
pancreatic cancer, as mea-
sured by IHC, is not signifi-
cantly associated with the 
outcome of FOLFIRINOX tre- 
atment and cannot be used 
as predictive biomarkers in 
this setting. Further studies 
with larger sample sizes that 
Table 4. Multivariate Cox regression analysis of factors associated 
with overall survival
Hazard 
ratio 95% CI P-value
ERCC1 Positive 0.444 0.112-1.762 0.248
Negative 1
ERCC2 Positive 1.102 0.258-4.711 0.895
Negative 1
ERCC4 Positive 3.294 0.653-17.103 0.156
Negative 1
GSTPi Positive 2.899 0.458-18.357 0.258
Negative 1
2nd or 3rd line therapy 2.171 0.370-12.726 0.390
1st line therapy 1
UICC Stage IV 1.049 0.080-13.803 0.971
III 1
Performance status (ECOG) 1 9.502 2.254-40.067 0.002
0 1
Neutrophil-to-lymphocyte ratio ≥5 6.016 1.195-30.292 0.030
<5 1
Initial dose modification 1.509 0.300-7.586 0.618
Original dose 1
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; 
ERCC, excision repair cross-complementing; GSTPi, glutathione S-transferase Pi; 
UICC, Union for International Cancer Control.
Table 5. Multivariate Cox regression analysis of factors associated 
with progression-free survival
Hazard 
ratio 95% CI P-value
ERCC1 Positive 0.371 0.123-1.119 0.078
Negative 1
ERCC2 Positive 0.971 0.294-3.205 0.962
Negative 1
ERCC4 Positive 2.150 0.539-8.579 0.278
Negative 1
GSTPi Positive 1.946 0.608-6.228 0.262
Negative 1
2nd or 3rd line therapy 2.556 0.782-8.356 0.120
1st line therapy 1
UICC Stage IV 0.693 0.130-3.702 0.668
III 1
Performance status (ECOG) 1 4.947 1.748-14.000 0.003
0 1
Neutrophil-to-lymphocyte ratio ≥5 1.653 0.552-5.230 0.393
<5 1
Initial dose modification 3.373 0.918-12.391 0.067
Original dose 1
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; 
ERCC, excision repair cross-complementing; GSTPi, glutathione S-transferase Pi; 
UICC, Union for International Cancer Control. 
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include examination of both protein and mRNA 
levels will be necessary to clarify the predic- 
tive value of these proteins. 
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Ⅰ 主論文 
Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for 
the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer. 
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